Table 2. Patient characteristics.
| Characteristics | All patients n = 282 | Patients with rsEMB n = 218 |
|---|---|---|
| number (%)* | ||
| Age > 50 years | 159 (56) | 118 (54) |
| Female gender | 54 (19) | 40 (18) |
| Entity | ||
| ICM | 103 (37) | 75 (34) |
| DCM | 144 (51) | 116 (53) |
| other | 35 (12) | 27 (12) |
| Gender mismatch | 57 (26) | |
| M→F | 9 (3) | 7 (3) |
| F→M | 70 (25) | 50 (23) |
| Initial treatment | ||
| TAC/MMF | 230 (82) | 187 (86) |
| TAC/m-TOR | 27 (10) | 27 (12) |
| CNI free | 3 (1) | 3 (1) |
| TAC/AZA | 1 (0) | 1 (0) |
| TAC | 1 (0) | 0 |
| Unkown/not applicable | 20 (7) | 0 |
| Maintenance therapy changed within the first year | ||
| No | 164 (75) | |
| Yes | 54 (25) | |
| Assist device | 66 (23) | 43 (20) |
| CMV status | ||
| Neg→neg | 62 (22) | 47 (22) |
| Pos→pos | 66 (23) | 52 (24) |
| Neg→pos | 74 (26) | 55 (25) |
| Pos→neg | 80 (28) | 64 (29) |
| Ischemic time > 240 min. | 128 (45) | 99 (45) |
| Post-operativ ICU time > 5 days | 133 (61) | |
| HTx in 2011 or later | 86 (31) | 63 (29) |
Absolute values with percentages in parentheses.
* Deviation from 100% due to rounding. m-TOR implicating either sirolimus or everolimus.